A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Pediatric Subjects With Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00460421

Enrollment

Registered

2007-04-16

Start date

2006-08-31

Completion date

2011-05-31

Last updated

2014-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

Oral Mucositis, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Palifermin, Kepivance

Brief summary

20010133 is an open-label, dose escalation study in pediatric patients with acute leukemias receiving myelotoxic therapy (high dose etoposide, cyclophosphamide and total body irradiation \[TBI\]) followed by hematopoietic stem cell transplant (HSCT). The study will evaluate the safety and pharmacokinetics of palifermin in pediatric patients. Three doses (40 μg/kg/day, 60 μg/kg/day, and 80 μg/kg/day) are to be evaluated in each age group (1 to 2, 3 to 11, and 12 to 16 years, respectively) using a conventional dose escalation design. Palifermin is administered for 3 consecutive days (Day -10 to Day -8, respectively) before the start of the conditioning regimen and for 3 consecutive days (Day 0 to Day +2) following HSCT. Patients will be enrolled simultaneously to each age group to identify a safe, well tolerated, efficacious dose in each age group. Patients will also be followed for secondary malignancies, progression-free survival (PFS) and overall survival (OS)

Interventions

DRUGPalifermin

Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).

RADIATIONTotal Body irradiation

DRUGChemotherapy

High dose etoposide, Cyclophosphamide

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Years to 16 Years

Healthy volunteers

Inclusion criteria

1. Acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) requiring HSCT 2. Age ≥ 1 and ≤ 16 years at screening 3. Lansky performance status \> 60% 4. Candidate for allogeneic HSCT protocol: * Adequate kidney function: Serum creatinine: ≤ 1.5 mg/dL or creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73m2 * Adequate liver function: Serum total bilirubin: ≤ 2.0 mg/dl; aspartate transaminase (AST)/alanine aminotransferase (ALT) ≤ 4.0 x institutional upper limits of normal (IULN); Albumin ≥ 2 g/dL * Adequate cardiac function: shortening fraction \> 29% documented by echocardiogram, or ejection fraction ≥ 50% documented by multigated acquisition scan (MUGA). * Adequate pulmonary function documented by corrected lung diffusion capacity test (DLCO) \> 50% or oxygen saturation of ≥ 92% on room air if unable to perform pulmonary function tests * Negative for human immunodeficiency virus (HIV), hepatitis C virus (HCV), human T cell lymphotropic virus (HTLV) 5. Identification of an HLA-compatible donor per institutional standards 6. Assent from a minor (if the child is capable of giving assent) per Department of Health and Human Services (DHHS) guidelines listed in 21CFR 50.55 and local Institutional Review Board (IRB) standards. 7. Serum amylase and lipase: ≤ 1.2 x IULN 8. Negative serum/urine pregnancy test for females with childbearing potential within 4 days before administration of the first palifermin dose 9. Agreement by males and females of reproductive potential to use an effective means of contraception 30 days prior to enrollment through Day +30 (end of treatment)

Exclusion criteria

1. Prior treatment with palifermin or other keratinocyte growth factors 2. Received an investigational product or device, with the exception investigational stem cell separators, in another clinical trial within 30 days before enrollment. 3. Known to have a life threatening infection not responding well to treatment 4. Past history of veno-occlusive disease of the liver 5. Known sensitivity to any Escherichia coli-derived products with grade 3 to 4 allergies to L-asparaginase \[grade 1 to 2 allergies to L-asparaginase will be allowed\]. 6. Receiving glutamine or any other medication to reduce the incidence of oral mucositis (OM) within 30 days before enrollment 7. Previous or concurrent malignancy other than entry diagnostic criteria and/or solid organ transplantation and/or treatment of congenital immunodeficiency 8. History of pancreatitis 9. Breastfeeding (giving)

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Dose Limiting Toxicities (DLTs)	Approximately 1 month duration (Day -10 through Day +16)	A DLT is appearance of side effects during treatment severe enough to prevent further increase in dosage or strength of treatment agent, or to prevent continuation of treatment at any dosage level. A DLT was defined as: Grade 3 or 4 AE \[based on Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) v3.0\] considered by the investigator to be related to palifermin with the exceptions: Grade 3 erythema, pruritus or rash that resolves within 7 days of the last dose of palifermin. The percentage of particiapnts with a DLT during the study was assessed.

Secondary

Measure	Time frame	Description
Incidence of Serum Palifermin Antibody Formation	Approximately 4 month duration (Through Day + 100 (+/- 40 days))	The percentage of participants developing palifermin antibodies during the study was assessed.
Incidence of Laboratory Abnormalities	Approximately 1 1/2 months duration (Through Day +30/End of Treatment)	The percentage of participants with a laboratory value outside the normal ranges during the study.
Pharmacokinetics of Palifermin, Clearence (CL) After the 1st Intravenous (IV) Bolus Injection for Multiple Dose Levels	Day -10	Clearence was estimated as dose divided by the area under serum concentration-time curve from time zero to infinity where the dose was given in amount palifermin actually administered.
Pharmacokinetics of Palifermin, Volume of Distribution at Steady State (Vss) After the 1st IV Bolus Injection for Multiple Dose Levels	Day -10	—
Pharmacokinetics of Palifermin, Terminal Half-life (t½,z) After the 1st IV Bolus Injection for Multiple Dose Levels	Day -10	The terminal half-life was calculated as ln(2)/lambda,z where lambda,z was estimated using at least three quantifiable serum concentrations of the terminal log-linear phase.
Incidence of Severe Adverse Events (AEs)	Approximately 1 1/2 months duration (Through Day +30/End of Treatment)	The percentage of participants with a severe AE during the study was assessed.
Pharmacokinetics of Palifermin, Area Under the Concentration Time Curve From Zero to the End of the Dosing Interval (AUCtau) After the 1st IV Bolus Injection for Multiple Dose Levels	Day -10	The AUC was estimated using the linear/log trapezoidal method for AUC0-tau from time zero to the end of the dosing interval (24 hours (hrs) post-dose) Data collected at time points: 0, 2 minutes (min), 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6, hrs, 10, hrs and 24 hrs post-dose.
Pharmacokinetics of Palifermin, AUCtau After the 3rd IV Bolus Injection for Multiple Dose Levels	Day -8	The AUC was estimated using the linear/log trapezoidal method for AUC0-tau from time zero to the end of the dosing interval (24 hours (hrs) post-dose) Data collected at time points: 0, 2 minutes (min), 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 6, hrs, 10, hrs and 24 hrs post-dose.
Long-Term Follow-Up: Incidence of Secondary Malignancies	Up to 4 years duration (Assessments performed on months 6, 9, 12 (+/- 30 Days) for the first year and then annually)	—
Long-Term Follow-Up: Progression Free Survival	Up to 4 years duration (Assessments performed on months 6, 9, 12 (+/- 30 Days) for the first year and then annually)	Progression free survival (PFS) was defined as the number of days between the date of first investigational product administration and the date when physical or radiological evidence of disease progression is determined or death (regardless of cause)
Long-Term Follow-Up: Overall Survival	Up to 4 years duration (Assessments performed on months 6, 9, 12 (+/- 30 Days) for the first year and then annually)	Overall survival was defined as the number of days from the date of first investigational product administration to the date of death (regardless of cause)
Pharmacokinetics of Palifermin, t½,z After the 3rd IV Bolus Injection for Multiple Dose Levels	Day -8	The terminal half-life was calculated as ln(2)/lambda,z where lambda,z was estimated using at least three quantifiable serum concentrations of the terminal log-linear phase.

Countries

United States

Participant flow

Recruitment details

This phase 1 dose-escalation study to evaluate the safety and pharmacokinetics (PK) of palifermin in pediatric subjects with acute leukemias undergoing myeloblative therapy and allogeneic hematopoietic stem cell transplant (HSCT) was performed in 7 centers in USA between 2006 and 2011.

Participants by arm

Arm	Count
Palifermin 40 µg/kg/Day Three subjects from each age group (1-2, 3-11, 12-16 years) were sequentially enrolled into the 3 planned dosing cohorts	9
Palifermin 60 µg/kg/Day Three subjects from each age group (1-2, 3-11, 12-16 years) were sequentially enrolled into the 3 planned dosing cohorts	9
Palifermin 80 µg/kg/Day Three subjects from each age group (1-2, 3-11, 12-16 years) were sequentially enrolled into the 3 planned dosing cohorts	9
Total	27

Baseline characteristics

Characteristic	Palifermin 60 µg/kg/Day	Palifermin 80 µg/kg/Day	Palifermin 40 µg/kg/Day	Total
Age, Categorical <=18 years	9 Participants	9 Participants	9 Participants	27 Participants
Age, Categorical >=65 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Categorical Between 18 and 65 years	0 Participants	0 Participants	0 Participants	0 Participants
Age, Continuous	7.4 years STANDARD_DEVIATION 5.6	8.0 years STANDARD_DEVIATION 6.6	7.4 years STANDARD_DEVIATION 6.3	7.6 years STANDARD_DEVIATION 5.9
Region of Enrollment United States	9 participants	9 participants	9 participants	27 participants
Sex: Female, Male Female	4 Participants	5 Participants	3 Participants	12 Participants
Sex: Female, Male Male	5 Participants	4 Participants	6 Participants	15 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	— / —
other Total, other adverse events	27 / 27
serious Total, serious adverse events	5 / 27

Outcome results

Primary

Incidence of Dose Limiting Toxicities (DLTs)

A DLT is appearance of side effects during treatment severe enough to prevent further increase in dosage or strength of treatment agent, or to prevent continuation of treatment at any dosage level. A DLT was defined as: Grade 3 or 4 AE \[based on Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE) v3.0\] considered by the investigator to be related to palifermin with the exceptions: Grade 3 erythema, pruritus or rash that resolves within 7 days of the last dose of palifermin. The percentage of particiapnts with a DLT during the study was assessed.

Time frame: Approximately 1 month duration (Day -10 through Day +16)